Searchable abstracts of presentations at key conferences in endocrinology

ea0064007 | Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study | BES2019

Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study

Constantinescu SM , Lefebvre A , Furnica RM , Maiter D

Introduction: Severe CushingÂ’s syndrome (CS) is defined by extremely high serum cortisol levels (usually >1000 nM), along with severe and deadly complications, including sepsis, heart failure, acute psychosis, vascular thrombosis, digestive haemorrhage and bowel perforation. Rapid control of such hypercortisolism is mandatory and has been shown to decrease operative mortality and complications. Oral treatments such as ketoconazole and metyrapone are often inadequate i...